AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026)

AbbVie (ABBV) has reported Other Non-Current Liabilities for 15 consecutive years, with $34.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 40.38% year-over-year to $34.6 billion in Q2 2026; TTM through Jun 2026 was $34.6 billion, a 40.38% increase from a year earlier, with the FY2025 full-year figure at $32.6 billion, up 50.32% from the prior year.
• Other Non-Current Liabilities was $34.6 billion for Q2 2026 at AbbVie, up from $34.1 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $34.6 billion in Q2 2026 and troughed at $13.8 billion in Q1 2022.
• A 5-year average of $22.3 billion and a median of $20.7 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities retreated 2.43% in 2022 and soared 50.32% in 2025, its largest moves.
• Over 5 years, Other Non-Current Liabilities stood at $16.4 billion in 2022, then increased by 21.4% to $19.9 billion in 2023, then gained by 8.93% to $21.7 billion in 2024, then soared by 50.32% to $32.6 billion in 2025, then grew by 6.25% to $34.6 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $34.6 billion (Q2 2026), $34.1 billion (Q1 2026), and $32.6 billion (Q4 2025), per Business Quant data.